- Poster presentation
- Open Access
Effect of antiretroviral therapy on homocysteine plasma concentrations in patients with AIDS
© Lopez et al; licensee BioMed Central Ltd. 2008
- Published: 10 November 2008
- Homocysteine Level
- Homocysteine Plasma
Antiretroviral (ARV) therapy is currently associated with longer survival and improved quality of life in AIDS patients. Several complications related to these drugs have been recently published, specifically thrombotic events. Hyperhomocysteinemia is an independent risk factor for atherothrombosis and venous thrombosis. Therefore, we aimed to determine the effect of ARV therapy on homocysteine plasma levels in patients with AIDS.
We included adult patients with HIV-infection naive for ARV drugs. ARV regimens were selected by the attending physician according to the DHHS Adult and Adolescents Treatment Guidelines criteria. Before and after 6 months of ARV treatment, we evaluated fasting and post oral methionine load (OML) plasma homocysteine, vitamins B6 and B12, and intra-erythrocyte and serum folate levels.
Serum concentrations of vitamins B6 and B12, serum and intra-erythrocyte folate levels, and plasma homocysteine concentrations in patients with AIDS before and 6 months after ARV therapy.
After 6-months ARV
Vitamin B6 (pg/mL)
Vitamin B12 (pg/mL)
Serum folic acid (ng/mL)
Intra-erythrocyte folate (ng/mL)
Fasting homocysteine (micromol/L)
Post-OML homocysteine (micromol/L)
Hyperhomocysteinemia, mostly that uncovered post-OML, is a frequent condition associated with ARV treatment.
This article is published under license to BioMed Central Ltd.